Form 4: Blueprint Medicines CFO Sells Shares to Cover Tax Obligations

Michael Landsittel, CFO of Blueprint Medicines, sold 5,284 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 5, 2025, Michael Landsittel, the Chief Financial Officer of Blueprint Medicines Corp, sold 5,284 shares of common stock.
• The sale was executed at a price of $88.8 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Landsittel directly owns 72,924 shares of Blueprint Medicines Corp.
• The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (selling shares to cover taxes) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Stakeholder Impact

• The sale of shares by an insider could be perceived negatively by some shareholders, although the explanation provided mitigates this concern.

Key Dates